Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0CG0N
|
||||
Former ID |
DIB004562
|
||||
Drug Name |
PRO-140
|
||||
Synonyms |
PRO-140 (sc); Humanized monoclonal anibody (subcutaneous, HIV infection), Progenics; PRO-140 (subcutaneous, HIV); CCR5 antagonist (subcutaneous, humanized mAb, HIV infection), Progenics; PRO-140 (subcutaneous, HIV), Progenics Pharmaceuticals
|
||||
Indication | Human immunodeficiency virus infection [ICD9: 279.3; ICD10:B20-B26] | Phase 2 | [525183] | ||
Company |
Progenics Pharmaceuticals Inc
|
||||
Target and Pathway | |||||
Target(s) | C-C chemokinereceptor type 5 | Target Info | Antagonist | [531384] | |
Pathway Interaction Database | IL12-mediated signaling events | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.